Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Radiation Oncology Journal ; : 85-94, 2018.
Article in English | WPRIM | ID: wpr-741945

ABSTRACT

Radiation-induced second malignancies (RISM) is one of the important late side effects of radiation therapy and has an impact on optimal treatment decision-making. Many factors contribute to the development of RISM such as age at radiation, dose and volume of irradiated area, type of irradiated organ and tissue, radiation technique and individual and family history of cancer. Exact mechanism of RISM is unknown. But nowadays, it is a growing concern in oncology because of the increased number of cancer survivors and efforts are being made to prevent or decrease the incidence of RISM. The primary search for articles was carried via Google Scholar and PubMed with keywords included ‘radiation induced malignancies, second malignancies, and chemotherapy induced malignancies’. Additional papers were found through references from relevant articles. In this review article, we have discussed about the pathogenesis, factors contributing to RISM, screening and prevention strategies of RISM.


Subject(s)
Humans , Drug Therapy , Incidence , Mass Screening , Neoplasms, Second Primary , Radiotherapy , Survivors
2.
Asian Spine Journal ; : 925-929, 2016.
Article in English | WPRIM | ID: wpr-125101

ABSTRACT

STUDY DESIGN: Retrospective observational study. PURPOSE: To identify the role of percutaneous vertebral biopsy in histopathological diagnosis of vertebral compression fractures and to identify the frequency of unexpected malignancy in vertebral compression fractures. OVERVIEW OF LITERATURE: Vertebral compression fractures are common in the Indian population. Magnetic resonance imaging and nuclear imaging have some limitations in the diagnosis of definitive pathology of vertebral compression fractures. Therefore, histological confirmation is necessary for definitive diagnosis and to plan appropriate management for patient. METHODS: A retrospective observational study was conducted involving 84 patients who underwent percutaneous vertebral biopsy between 2010 and 2014. We performed C-arm guided percutaneous transpedicular core vertebral biopsy of vertebral compression fractures under combination of local anesthesia and intravenous conscious sedation. RESULTS: Sufficient biopsy material was obtained in 79 of the 84 cases. In the other five cases, biopsy material was not sufficient for reporting. Out of the 79 cases, osteoporotic pathology was detected in 69 patients, malignancy was detected in 8 patients and no pathology was found in 2 patients. Two patients with distant metastases to vertebra were identified. Primary spinal malignancy was detected in 6 patients (1 unsuspected plasmacytoma, 5 diagnosed malignancy preoperatively). So, the frequency of unsuspected malignancy of this study was 1.19% (1/84). None of the patients had any complications. CONCLUSIONS: C-arm guided percutaneous transpedicular vertebral biopsy is useful in obtaining definitive histopathological diagnosis of vertebral compression fractures, especially in differentiating malignant and non-malignant vertebral compression fractures and helping plan appropriate management of patients. The rate of unexpected malignancy in vertebral compression fracture was 1.19%.


Subject(s)
Humans , Anesthesia, Local , Biopsy , Biopsy, Needle , Conscious Sedation , Diagnosis , Fractures, Compression , Magnetic Resonance Imaging , Neoplasm Metastasis , Neoplasms, Second Primary , Observational Study , Osteoporosis , Pathology , Plasmacytoma , Retrospective Studies , Spine
3.
Rev. cuba. med ; 54(2): 107-118, abr.-jun. 2015. ilus, tab
Article in Spanish | LILACS, CUMED | ID: lil-752347

ABSTRACT

OBJETIVO: analizar las causas de muerte en pacientes con diagnóstico de linfoma de Hodgkin. MÉTODOS: se realizó un estudio retrospectivo-descriptivo en el Servicio de Hematología del Hospital Clinicoquirúrgico "Hermanos Ameijeiras". La muestra quedó constituida por 443 pacientes, de los 619 diagnosticados desde enero de 1983 hasta diciembre del 2008, de ellos 287 (64,8 %) se encontraban vivos al final del estudio y 156 (35,2 %) habían fallecido. RESULTADOS: la recaída/progresión del linfoma de Hodgkin fue la causa más importante de muerte (125 pacientes, 80 %), independiente de la edad de presentación de la enfermedad, la modalidad de tratamiento empleada y el tiempo de evolución. El 20 % restante fue por segundas neoplasias en 10 pacientes (6,4 %), complicaciones del tratamiento en 8 (5,1 %), complicaciones infecciosas fatales en 2 (1,2 %) y enfermedad cardiovascular en 3 (1,9 %). En 8 pacientes (5,1 %) no se precisó la causa de muerte. Predominaron las segundas neoplasias en pacientes de 40-59 años, que recibieron la modalidad de tratamiento combinada y tenían menos de 10 años de evolución. CONCLUSIONES: la recaída/progresión del linfoma de Hodgkin permanece como causa más importante de muerte, independientemente de la edad de presentación, la modalidad de tratamiento empleada y el tiempo de evolución. Sería importante identificar precozmente los casos refractarios al tratamiento convencional para utilizar la modalidad terapéutica más apropiada para la curación.


OBJECTIVE: determine the causes of death in patients diagnosed with Hodgkin lymphoma. METHODS: a retrospective descriptive study was conducted at the Department of Hematology, "Hermanos Ameijeiras" Hospital. The sample was composed of 443 patients, 619 diagnosed from January 1983 to December 2008. 287 of them (64.8 %) were alive at the end of the study, 156 (35.2 %) had died. RESULTS: the relapse/progression of Hodgkin lymphoma was the most important cause of death (125 patients, 80 %), regardless of the age of the disease onset, the type of treatment used and the time of evolution. The remaining 20 % was due to: second malignancies in 10 patients (6.4 %), complications of treatment in 8 (5.1 %), fatal infectious complications in 2 (1.2 %) and cardiovascular disease in 3 (1.9 %). In 8 patients (5.1 %) the cause of death was not specified. Secondary malignancies prevailed in patients aged 40-59 years who received combined treatment and had less than 10 years of evolution. CONCLUSIONS: relapse/progression of Hodgkin lymphoma remains a leading cause of death, regardless of the onset age, the treatment modality used and the time of evolution. It would be important to identify early cases refractory to conventional treatment to use the most appropriate therapeutic modality for healing.


Subject(s)
Humans , Hodgkin Disease/diagnosis , Hodgkin Disease/mortality , Neoplasm Recurrence, Local , Recurrence , Epidemiology, Descriptive , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL